-
ABOUT US
-
R&D
-
AGORA
-
PR
-
RECRUITMENT
-
CONTACT
AGORA
Patent
Patent status
It is a unique, first-in-class technology that uses ApoB100 as the molecular target for a new MOA obesity immunotherapy treatment.
Patents: Total 17 < 3 Registrations, 14 Applications (1 PCT/13 Individual country entries) >
| No. | Patents | Date | Status | Country | Remark |
|---|---|---|---|---|---|
| 1 | (US 7,829,667) | 2004 | Registration | USA |
Peptides for immunotherapy (B4T, OTP5 included in scope of rights) |
| 2 | 10-2261457-00-00 | 2020 | Korea | Peptides for immunotherapy | |
| 3 | 17/823,180 | 2023 | USA |
Peptides for immunotherapy (Expedited examination for OTP5) |
|
| 4 | PCT/KR2021/009453 | 2021 | Application | WO |
Peptides for immunotherapy (Comprehensive content of 3HOTP) |
| 5 | PCT | 2022 | Korea, USA, EU, China and 9 other countries |
PCT entry application (13 countries) |